AETC ShareSpot: New HIV Meds Updates
Thursday, August 30, 2018
From the AETC ShareSpot - Three new HIV Meds Updates blog stories summarize findings presented at AIDS 2018.
They include the following:
- Results of the U=U in PARTNER2 Study of MSM
- Results of 2-drug ARV regimen studies: Dolutegravir + 3TC in Initial Therapy
- The first FDA approved protease inhibitor-containing, single-tablet regimen: Darunavir/Cobicistat/FTC/TAF, More Data from EMERALD Switch Study
HIV Meds Updates are written by Susa Coffey, MD, Co-investigator and Medical Editor of the AETC NCRC and UCSF CHI, and stories are posted as new HIV medication information becomes available.
Browse for More
Total views: 242